Physician profile
Barry M Glick
NPI 1013903509
$24,784.63
in general payments reported to CMS, 2019-2025
68 companies · $3,110 in 2025
The $3,110 reported for 2025 was more than what 96% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,400 · 2020: $3,145 · 2021: $4,366 · 2022: $4,426 · 2023: $3,111 · 2024: $3,227 · 2025: $3,110.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,421 · Education: $27.61.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,420.54 |
| Education | $27.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,539.73 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $2,012.49 | 2019-2025 | |
| Pfizer INC. | $1,932.41 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,665.82 | 2019-2025 | Airsupra, Farxiga, Lokelma |
| Amgen INC. | $1,568.45 | 2019-2025 | Repatha, Otezla, Evenity |
| Janssen Pharmaceuticals, INC | $1,401.37 | 2019-2024 | Xarelto |
| Glaxosmithkline, LLC. | $1,268.65 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $1,125.92 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $967.58 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Novartis Pharmaceuticals Corporation | $765.67 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $603.37 | 2019-2025 | Xifaxan, Trulance |
| Corcept Therapeutics | $561.29 | 2023-2025 | Korlym |
| Bayer Healthcare Pharmaceuticals INC. | $506.73 | 2021-2025 | |
| Amarin Pharma, INC. | $492.43 | 2019-2023 | |
| E.R. Squibb & Sons, L.L.C. | $469.59 | 2019-2023 | Eliquis |
Show all 68 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barry Glick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.